On September 17, 2019, IDL Biotech will launch the company's rapid test for typhoid fever, TUBEX TF, in Kenya. Read more here
IDL Biotech lanserar TUBEX TF i Kenya
läs mer
Nyheter
Senaste nytt.
IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA
IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company's rapid test for bladder cancer. Read the press release here (in swedish)
Abstract shows the value of UBC Rapid
An abstract presented in Tumor Biology (July 2019: 1-74) shows the value of UB® Rapid, for accurate diagnosis and follow-up in bladder cancer. Read the press release here (in swedish)
Meet IDL Biotech at Coalition against Typhoid Fever
Every two years, the Coalition against Typhoid, based at the Sabin Vaccine Institute (Sabin), convenes the International Conference on Typhoid and Other Invasive Salmonelloses. The 11th International Conference on Typhoid and Other Invasive Salmonelloses will be held...
German study recommends UBC® Rapid to be added in the diagnostics and follow-up of high risk bladder cancer
International Journal of Molecular Sciences has published a study on UBC® Rapid. In total 530 urine samples was included in the multicenterstudy. The author of the study concluded that elevated values of UBC® Rapid Test in urine are higher in patients with...
What is Typhoid fever?
Typhoid fever is a water and food-borne infectious disease caused by the bacterium, Salmonella enterica. The World Health Organization identifies typhoid fever as a serious public health issue. There are an estimated 11-20 million new cases reported annually,...
6 things you need to know about Bladder Cancer
Bladder cancer is the ninth most commonly diagnosed cancer in the world with an estimated 430 000 new cases reported in 2012. Men are more than three times more likely to get bladder cancer than women. Smoking is a major cause of bladder cancer. Exposure to industrial...
What is cytokeratins?
Cancer affects everyone the young and old, the rich and poor, men, women and children and represents a tremendous burden on patients, families and societies. Cancer is one of the leading causes of death in the world. Normal cells are constantly dividing, but in...
Patent approved in Europe
During 2015 the patent Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof was approved in Sweden. In September 2017 the patent was approved in China. The patent has now also been approved in Europe and is valid until 2034.
Positive results for TPS®
Results from a Czech Republic study. Breast cancer represents 24 % of all cancer occurring in women. Breast cancer is the most common malignancy and the second most frequent cause of death by cancer in women. Although the incidence rate of breast cancer has been...
